What happens when the first treatments used in Crohn’s disease and ulcerative colitis are not enough? What are the new biological medicines, the targeted treatments taken by mouth, and the other options?
What is inflammatory bowel disease?
Inflammatory bowel diseases (IBD) are conditions that cause chronic inflammation in the digestive system. They fall into two main groups:
Crohn’s disease: can affect any part of the digestive system from the mouth to the anus. It is most often seen in the small bowel and the large bowel.
Ulcerative colitis: affects the large bowel. It usually starts in the rectum and can spread further up the bowel.
In both diseases there can be abdominal pain, diarrhoea, blood in the stool, weight loss, tiredness and anaemia.
The aim of treatment is not only to reduce symptoms. It is to bring the inflammation in the bowel under control, let the bowel tissue heal, and keep the disease quiet for a long time.
What does “fourth-line treatment” mean?
In IBD there are no four treatment steps that are clearly defined and apply to everyone.
In everyday use, however, “fourth-line treatment” may be used to describe the advanced treatment options considered after several earlier treatments have not worked well enough or have stopped working.
For example, in some patients the disease can stay active despite steroids, medicines that regulate the immune system and biological treatments.
This does not mean there are no treatment options left.
Today, thanks to new medicines that work through different mechanisms, it may be possible to bring the disease under control even in patients who have not benefited from one or more treatments.
On the other hand, some patients with severe disease may need to start advanced treatment earlier. Not every patient has to go through all the medicines in turn.
Why can a biological treatment stop working?
In some patients a biological treatment works at first but becomes less effective over time.
There are different reasons for this.
The body can develop antibodies against some biological medicines. The level of the medicine in the blood can then fall, or it can become less effective.
In other patients the inflammation in the bowel continues even though the medicine is present at a good enough level. In that case it may be necessary to switch to a medicine with a different mechanism of action to control the disease.
Before deciding that a treatment has failed, it should be checked whether the disease really is active.
This is because diarrhoea or abdominal pain does not always come from active bowel inflammation. Infections, irritable bowel syndrome, bile acid diarrhoea or structural problems in the bowel can cause similar symptoms.
So changing medicine based on the patient’s symptoms alone is not always right.
Which Treatments Can Be Used at the Advanced Stage?
1. New-generation biological medicines
Biological medicines are treatments that target specific mechanisms in the immune system that drive inflammation.
In addition to the anti-TNF medicines that have been used in IBD for many years, new medicines acting through different mechanisms have been developed.
Anti-TNF treatments
Infliximab and adalimumab are well-known examples of this group.
These medicines reduce the effect of a substance called TNF, which plays a part in inflammation.
In some patients who do not respond to their first anti-TNF treatment, or who lose their response later, it is possible to switch to another medicine in the same group.
In some situations, however, switching to a different group of medicines may be more appropriate.
Vedolizumab
Vedolizumab works by reducing the movement of immune cells into the bowel tissue.
Because its action is focused on the bowel, it is an important treatment option for some patients.
It can be used in both Crohn’s disease and ulcerative colitis.
Ustekinumab
Ustekinumab targets a component shared by two substances in the immune system called interleukin-12 and interleukin-23.
It is one of the biological treatments used in Crohn’s disease and ulcerative colitis.
It can also be considered in patients who have previously used other biological medicines.
IL-23 inhibitors
These medicines target interleukin-23, an immune system signal that plays a part in causing bowel inflammation.
This group includes medicines such as risankizumab, mirikizumab and guselkumab.
These treatments offer new options especially for some patients who have not benefited enough from other biological treatments before.
However, whether these medicines can be used in Crohn’s disease or ulcerative colitis depends on licensing and reimbursement rules, which differ from country to country.
2. Targeted treatments taken by mouth
Not all advanced treatments are given by injection or drip.
Some new medicines can be taken as tablets.
JAK inhibitors
JAK inhibitors suppress some of the signalling pathways inside immune cells that keep inflammation going.
Tofacitinib and upadacitinib are examples of medicines in this group.
Upadacitinib is one of the advanced treatment options that can be considered in both ulcerative colitis and Crohn’s disease. Tofacitinib is used in ulcerative colitis.
One of the important advantages of these medicines is that they can be taken by mouth.
But they are not suitable for every patient.
In particular, older age, smoking, heart and blood vessel disease, a history of blood clots and certain cancer risks must be taken into account when choosing treatment.
Before treatment, screening for infection and the necessary blood tests are done.
S1P receptor modulators
Ozanimod and etrasimod are examples of medicines in this group.
These medicines reduce the movement of some immune cells from the lymph tissue into the bloodstream, which helps control inflammation in the bowel.
They are among the advanced treatment options taken by mouth that can be used in ulcerative colitis.
Before treatment, the patient’s heart rhythm, the medicines they take, their history of infections and other health problems should be assessed.
Advanced Treatment in Crohn’s Disease
In Crohn’s disease, the choice of treatment is not based only on how severe the diarrhoea or abdominal pain is.
It also matters whether the disease is in the small bowel or the large bowel, and whether a narrowing (stricture), fistula or abscess has developed.
In patients who have used an anti-TNF treatment before without enough response, medicines acting through different mechanisms can be considered.
Risankizumab, guselkumab, mirikizumab, ustekinumab and upadacitinib are among these options.
Which medicine is chosen depends on the response to earlier treatments and on the patient’s other health problems.
For example, if there is a marked narrowing or an abscess in the bowel, simply changing the medicine may not be enough. Endoscopic treatment, drainage of the abscess or surgery may be needed.
In Crohn’s disease, the aim of advanced treatment is not only to reduce symptoms but to control the bowel inflammation and so lower the risk of permanent damage.
Advanced Treatment in Ulcerative Colitis
In ulcerative colitis, bloody diarrhoea that continues despite treatment, more frequent bowel movements, or active inflammation seen at colonoscopy may call for treatment to be reviewed.
In patients who have used a biological treatment before, different biological medicines or targeted treatments taken by mouth can be used.
Ustekinumab, IL-23 inhibitors and JAK inhibitors are among these options.
Some medicines may work better than others in groups of patients who have already used other treatments. But this does not mean that medicine is the best option for every patient.
In particular, the choice of medicine can change in situations such as a high risk of serious infection, heart and blood vessel disease, plans for pregnancy, and older age.
Patients who have a severe flare of ulcerative colitis may need to be admitted to hospital. Their treatment approach is different from that of patients followed up in the outpatient clinic.
What Is Checked Before Changing Medicine?
When there is no response to treatment, the first step is not always to start a new medicine.
The gastroenterologist should first assess how active the disease is and why the previous treatment failed.
For this, blood tests, CRP, faecal calprotectin, tests for infection, colonoscopy or, where needed, bowel imaging can be used.
For some biological medicines, the level of the medicine in the blood and antibodies against it can also be measured.
Based on this assessment, it may be decided to adjust the dose of the current medicine, switch to another medicine, or use a different form of treatment.
Can More Than One Advanced Treatment Be Used Together?
In some patients with IBD that does not respond to treatment, using two different advanced treatments together is being studied.
This approach aims to control different inflammatory mechanisms at the same time.
But using two biological medicines, or a biological medicine together with another targeted treatment, is not yet standard practice for all patients.
Such treatments need careful assessment because of the risk of serious infections and other side effects.
They may be considered only in selected patients, in experienced centres and under close follow-up.
Do Advanced Treatments Have Side Effects?
As with any medicine, advanced IBD treatments can have side effects.
These vary with the medicine used.
Some medicines can increase the risk of infection. In others, liver tests, blood cells or cholesterol levels can be affected.
With some medicines, such as JAK inhibitors, the risks of heart and blood vessel events and blood clots must be considered in particular.
Before treatment, screening for infections such as tuberculosis and hepatitis B may be needed.
It is also important to check vaccination status.
Patients should be followed up regularly during treatment and should not stop their medicines without their doctor’s advice.
When Is Surgery Needed?
The development of advanced medical treatments has not completely removed the need for surgery.
In Crohn’s disease, surgery may be needed because of narrowing of the bowel, an abscess, a fistula or other complications.
In ulcerative colitis, surgery may be considered for severe disease that cannot be controlled with medicines, serious bleeding, perforation of the bowel, or cancer-related situations.
Surgery does not always mean that medicines have completely failed. In some situations it may be the most suitable option for bringing the disease under control.
Frequently Asked Questions
I have used several biological medicines. Have I run out of treatment options?
No. Today there are many advanced treatments that work through different mechanisms. But which options are suitable depends on the medicines used before and on the current state of the disease.
Do the new-generation medicines cure the disease completely?
IBD is a chronic disease. Current medicines can keep the disease under control for a long time, reduce bowel inflammation and improve quality of life. But medical treatment does not guarantee that the disease will go away for good.
Can my disease be kept under control without steroids?
Yes. One of the main aims of advanced treatment is to keep the disease under control for a long time without steroids. Steroids are not suitable for long-term maintenance treatment.
Can I carry on with normal life while using advanced treatment?
Many people whose disease is under control can carry on with their daily life, work and social activities. Even so, regular follow-up and the recommended check-ups are important.
Are the new medicines available in Turkey?
The licensing and reimbursement status of medicines in Turkey differ from one medicine to another and can change over time. A medicine being recommended in international guidelines does not mean it can be prescribed for every patient in Turkey or that it is covered by the Social Security Institution (SGK).
Conclusion
If Crohn’s disease or ulcerative colitis continues despite several treatments, it does not mean the treatment options have run out.
New-generation biological medicines and targeted treatments taken by mouth offer important options for patients who have not had enough response before.
Even so, not every new medicine is suitable for every patient.
The best approach is to build a personal treatment plan by looking at disease activity, previous treatments, possible complications and the patient’s general health together.
Key message: In IBD treatment the aim is not only to reduce diarrhoea and abdominal pain, but to bring the bowel inflammation under control, keep the patient well without steroids, and prevent long-term damage to the bowel.
This article is for general information. Choice of medicine, dose changes and stopping treatment should be decided after an assessment by a gastroenterologist.
This article was prepared with particular reference to the 2025 AGA guideline on Crohn’s disease, the 2024 AGA guideline on ulcerative colitis and the 2026 ECCO recommendations on ulcerative colitis. Current guidelines stress that, as well as the medicines used before, the severity of the disease, safety and the patient’s characteristics should be considered together when choosing treatment.